

RESULTS OF THE EGM

Paris, France and Cambridge, UK – 6th December 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, held an Extraordinary General Meeting (“EGM”) on Monday 5 December. The meeting was convened to approve various resolutions to allow the Company to achieve its strategic goals. The results of the EGM are set out below:

Resolution	Votes For		Votes Against		Results
	Number	%	Number	%	
1) Delegation of authority granted to the Board of Directors to issue ordinary shares in the Company and/or securities granting access to the Company’s share capital, with the elimination of the shareholders’ preferential subscription right in favour of a specific category of people	5 527 349	69.43	2 433 950	30.57	Adopted
2) Delegation of authority to the Board of Directors to issue ordinary shares in the Company and/or securities granting access to the Company’s share capital, with the elimination of the shareholders’ preferential subscription right in favour of a specific category of people, in the context of the system provided for by the French TEPA Act and in accordance with the provisions of Article L. 225-138 of the French Commercial Code	5 527 349	69.43	2 433 950	30.57	Adopted
3) Delegation of authority to the Board of Directors to issue ordinary shares in the Company and/or securities granting access to the Company’s share capital, with the maintenance of the preferential subscription right	7 715 342	96.91	245 957	3.09	Adopted
4) Authorisation given to the Board of Directors in the event of a capital increase, with or without the elimination of the shareholders’ preferential subscription right, to increase the number of shares to be issued	7 528 673	94.57	432 626	5.43	Adopted
5) Global limitation of authorisations	7 690 250	96.59	271 049	3.41	Adopted
6) Delegation of powers granted to the Board of Directors to issue warrants giving access to new shares with the elimination of the shareholders’	6 833 259	93.72	457 718	6.28	Adopted

preferential subscription right in favour of designated persons ¹					
7) Delegation of powers granted to the Board of Directors to issue warrants giving access to new shares with the elimination of the shareholders' preferential subscription right in favour of a designated person	5 683 306	71.39	2 277 993	28.61	Adopted
8) Delegation of authority to the Board of Directors to issue ordinary shares and/or securities granting access to the Company's share capital in favour of members of a company savings scheme (plan d'épargne entreprise)	746 461	9.38	7 214 838	90.62	Rejected
9) Powers to complete formalities	7 871 299	98.87	90 000	1.13	Adopted

Number of shareholders having participated (by voting form, by giving proxy or by being present):
77 shareholders representing 7 961 299 shares

- End -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and molecular platform, genesig® Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

¹ Shareholders holding BSA 16/05/01 did not vote on this resolution

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

NOVACYT

Graham Mullis

Chief Executive Officer

+44 (0)7901 514 121

graham.mullis@novacyt.com